Literature DB >> 20584763

Quantitative expression of RIG-like helicase, NOD-like receptor and inflammasome-related mRNAs in humans and mice.

Maciej Lech1, Alejandro Avila-Ferrufino, Veronika Skuginna, Heni Eka Susanti, Hans-Joachim Anders.   

Abstract

The cell-type-, organ- and species-specific expression of the surface and endosomally located Toll-like receptors are well described but little is known about the respective expression profiles of cytosolic pattern recognition molecules. We therefore determined the mRNA expression levels of 15 cytosolic pattern recognition molecules in 11 solid organs of human and mice. Human organs revealed lower mRNA levels of most molecules as in spleen but at least 2-fold higher were inflammasome-related NOD, leucine-rich repeat and pyrin domain-containing protein 1-3 (NLRP1-3) and -12 in brain, LGP2, retinoic acid-inducible gene I (RIG-I) and NLRP10 in liver, NLRP10 in small intestine, LGP2, RIG-I, NAIP, NLRP2 and -3 in testis and RIG-I, NLRP2 and -10 in muscle. In mice, most organs also expressed lower mRNA levels compared with spleen. Only NLRP6 in liver, NAIP and NLRP6 in small intestine, LGP2, nucleotide-binding oligomerization domain 1 (NOD1), NLRP1, -2, -6, -10 and -12 in colon and MDA5, RIG-I, NLRC4, NOD1, -2, NLRP1, -2, -6, -10 and -12 mRNA levels in kidney were higher. Resting human and mouse monocytes and T cells expressed most molecules and produced IL-1 beta and CCL5/RANTES upon activation. However, murine monocytes strongly up-regulated, whereas human monocytes down-regulated receptor expression upon activation. These data suggest that the cell-type-, organ- and species-specific expression and regulation need to be considered in the design and interpretation of related studies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20584763     DOI: 10.1093/intimm/dxq058

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  60 in total

Review 1.  Inflammasomes in intestinal inflammation and cancer.

Authors:  Grace Y Chen; Gabriel Núñez
Journal:  Gastroenterology       Date:  2011-10-15       Impact factor: 22.682

Review 2.  An update on the role of the inflammasomes in the pathogenesis of kidney diseases.

Authors:  Murthy N Darisipudi; Felix Knauf
Journal:  Pediatr Nephrol       Date:  2015-07-16       Impact factor: 3.714

3.  Toll-like receptor 4-induced IL-22 accelerates kidney regeneration.

Authors:  Onkar P Kulkarni; Ingo Hartter; Shrikant R Mulay; Jan Hagemann; Murthy N Darisipudi; Santhosh Kumar Vr; Simone Romoli; Dana Thomasova; Mi Ryu; Sebastian Kobold; Hans-Joachim Anders
Journal:  J Am Soc Nephrol       Date:  2014-01-23       Impact factor: 10.121

4.  Nucleotide-binding and oligomerization domain-like receptors and retinoic acid inducible gene-like receptors in human tonsillar T lymphocytes.

Authors:  Terese Petterson; Anne Månsson; Kristian Riesbeck; Lars O Cardell
Journal:  Immunology       Date:  2011-02-22       Impact factor: 7.397

5.  NLR functions beyond pathogen recognition.

Authors:  Thomas A Kufer; Philippe J Sansonetti
Journal:  Nat Immunol       Date:  2011-02       Impact factor: 25.606

Review 6.  Intracellular sensing of microbes and danger signals by the inflammasomes.

Authors:  Gabor L Horvath; Jacob E Schrum; Christine M De Nardo; Eicke Latz
Journal:  Immunol Rev       Date:  2011-09       Impact factor: 12.988

Review 7.  Gut-liver axis: role of inflammasomes.

Authors:  Manan Bawa; Vivek A Saraswat
Journal:  J Clin Exp Hepatol       Date:  2013-04-15

Review 8.  Innate immune signalling at the intestinal epithelium in homeostasis and disease.

Authors:  Johanna Pott; Mathias Hornef
Journal:  EMBO Rep       Date:  2012-07-17       Impact factor: 8.807

Review 9.  NLRs in immune privileged sites.

Authors:  Holly L Rosenzweig; Stephen R Planck; James T Rosenbaum
Journal:  Curr Opin Pharmacol       Date:  2011-07-29       Impact factor: 5.547

Review 10.  The role of innate immunity in HBV infection.

Authors:  Qiuju Han; Cai Zhang; Jian Zhang; Zhigang Tian
Journal:  Semin Immunopathol       Date:  2012-07-20       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.